drugset / Trial / NCT06151106
Chidamide and Duvalisibon for the Treatment of Refractory/Relapsed Peripheral T-cell Lymphoma
Phase 2
Recruiting
33 enrolled
The First Affiliated Hospital of Xiamen University
Dongguan People's Hospital · collabFujian Cancer Hospital · collabHuizhou Municipal Central Hospital · collabShanxi Province Cancer Hospital · collabSun Yat-sen University · collabThe First Affiliated Hospital with Nanjing Medical University · collabZhangzhou Affiliated Hospital of Fujian Medical University · collab
NaSingle-groupOpen-labelTreatment
Summary
To determine the efficacy and safety of Chidamide combined with Duvalisib in the treatment of refractory/relapsed peripheral T-cell lymphoma.
Timeline
- Start
- 2023-11-22
- Primary completion
- 2026-12-31
- Completion
- 2027-12-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Duvalisib | Unknown | — | — |
| Subject | Tucidinostat | Small molecule | — | — |